Please login to the form below

Not currently logged in
Email:
Password:

Tysabri

This page shows the latest Tysabri news and features for those working in and with pharma, biotech and healthcare.

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).

Latest news

More from news
Approximately 5 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Elan / Perrigo. Acquisition. Tysabri royalty stream, R&D programmes/ EU HQ &operations.

  • Pharma deals during July 2013 Pharma deals during July 2013

    In addition to this is the very attractive tiered double digit royalty stream from Tysabri. ... Sales of Tysabri in 2012 were $1.6bn. Acquisitions - a route to bolstering a core business.

  • Pharma deals during May 2013 Pharma deals during May 2013

    The Elan/ Royalty Pharma saga began following Biogen Idec's decision in February to buy out the Tysabri rights from Elan for $3.25bn. ... Following the close of the Tysabri deal in early April, Elan went on a spending spree in May.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration ... Tysabri's sales amounted to $1.6bn

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    Prior to Momenta, Ottmer spent 16 years at Biogen in a variety of leadership roles including senior vice president, strategy and emerging businesses, head of Tysabri business, chief of staff to

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise. ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Richard Kim led Tysabri programme at Biogen Idec. XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs. ... He joined XenoPort from Biogen Idec where he was joint programme team leader for

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    Between May 2019 and May 2020, there was a reduction in several key treatments: Lemtrada, Tysabri and Gilenya. ... Lemtrada is a monoclonal antibody (MAB) given by infusion. Tysabri, or natalizumab, is also an infusion injection.

  • It's time to change the conversation

    connections. While promotional spend on their drug Tysabri at launch was focused on specialist detailing and medical events, the promotional mix has evolved with increased direct to consumer spend and direct

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...